Seroprotection against serogroup C meningococcal disease

Conterno, Lucieni O.; Heath, Paul T.
June 2008
BMJ: British Medical Journal (International Edition);6/28/2008, Vol. 336 Issue 7659, p1447
Academic Journal
In this article the author comments on a study that examined the persistence of serum bactericidal antibody against meningococcal serogroup C among adolescents who were immunized with serogroup C meningococcal conjugate vaccines between the ages of 6-15. The findings suggest that the vaccine is more effective when given during the second decade of life rather than the first. The author notes that the study speaks to the importance of understanding the relationship between age and vaccination.


Related Articles

  • Indian meningitis vaccine to save 250 million lives in Africa.  // Africa Health;Mar2011, Vol. 33 Issue 3, p10 

    The article reports on the administration of a new Indian vaccine against meningitis to nearly 250 million children and adults in sub-Saharan Africa.

  • New vax could virtually eliminate epidemic in Africa's meningitis belt.  // PharmacoEconomics & Outcomes News;7/10/2010, Issue 607, p7 

    The article discusses research on MenAfriVac, a new low-cost vaccine that will reportedly eliminate the epidemic form of meningitis A, referencing a study by P. Moszynski published in an issue of the "British Medical Journal."

  • Meningococcal C conjugate vaccines. Reid, Stewart // New Zealand Doctor;12/13/2006, p15 

    The article focuses on meningococcal C conjugate vaccines. Group B has been the most significant meningococcal serogroup in New Zealand since 1991 which accounts for about 75 percent of isolates. It describes three protein conjugate group C capsular polysaccharide vaccines, namely Meningitec...

  • Meningitis Vaccine Purification: Quality Control of Ultrafiltration Membrane Porosity. Shwu-Maan Lee; Kruse, Bob; Robinson, Amy // BioPharm International;Aug2010, Vol. 23 Issue 8, p38 

    The article focuses on the introduction of NeisVac-C, a meningitis vaccine in 2000 in Great Britain. It states that the vaccine is the only meningitis conjugate vaccine that uses the de-O-acetylated form of group C meningococcal polysaccharide (GCMP). It mentions the need to consider the...

  • Meningitis Angels in Denver to Commemorate World Meningitis Day.  // Biomedical Market Newsletter;5/28/2011, p153 

    The article reports that the patient advocacy group Meningitis Angels in Denver, Colorado will be commemorating the World Meningitis Day to educate the public on preventative vaccines for meningitis. The group is committed to raise awareness about meningococcal disease, an often fatal condition...

  • Which of the 2 meningococcal vaccines should you use? Dempsey, Amanda F.; Freed, Gary L. // Patient Care for the Nurse Practitioner;Jul2007, Vol. 10 Issue 7, p18 

    The article offers clinical information on meningococcal disease. It compares the characteristics of conjugate vaccine MCV4 and meningogoccal vaccine MPSV4. It explains the clinical indications for using each vaccine. The article also discusses various concerns and inquiries about the safety of...

  • Meningitis outbreak contained with vaccination campaign underway.  // African Business News;5/22/2013, p40 

    The article reports on the containment of meningitis outbreak in the Upper Nile State of Sudan through a mass vaccination campaign.

  • Meningitis vaccination concluded after reaching up to 124,000 people.  // African Business News;5/29/2013, p36 

    The article reports on the conclusion of the mass-immunization campaign in Upper Nile State, South Sudan aimed at contain the meningitis outbreak declared on April 30, 2013.

  • Current Issues.  // PharmacoEconomics & Outcomes News;12/11/2010, Issue 618, p2 

    The article announces that the mass vaccination campaign against meningitis A in Africa using MenAfriVac will start in Burkina Faso on December 6, 2011.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics